Table 1.
Characteristics of the 6207 subjects
| Mean (range) or Frequency (%) | |
|---|---|
| Date of birth (year) | 1958 (1908–1997) |
| Date of baseline (year) | 2005 (1994–2020) |
| Years of follow-up | 8.1 (0.1–25.1) |
| Ethnic group | |
| Jewish | 1205 |
| French-Canadian | 520 |
| Other white | 4153 |
| African-American | 90 |
| Asian | 129 |
| Other | 110 |
| BRCA1 | 3623 (58.4%) |
| BRCA2 | 2584 (41.6%) |
| Country of residence | |
| USA | 3271 (52.7) |
| Canada | 2936 (47.3) |
| Breast cancer at baseline | |
| No | 3381 (54.5%) |
| Yes | 2819 (45.5%) |
| Missing | 7 |
| Ovarian cancer at baseline | |
| No | 5456 (87.9) |
| Yes | 653 (10.5) |
| Missing | 98 |
| Hormone replacement therapy | |
| No | 4024 (64.9) |
| Yes | 2180 (35.1) |
| Missing | 3 |
| Oophorectomy | |
| No | 1977 (32.0) |
| Yes | 4206 (68.0) |
| Missing yes/no | 24 |
| Mean year of oophorectomy | 2003.6 (1945–2021) |
| Mean age of oophorectomy | 46.9 (13–83) |
| Skin cancer at baseline | |
| No | 5952 (95.5) |
| Yes | 255 (4.1) |
| First degree relative with skin cancer | |
| No | 2403 (93.3) |
| Yes | 173 (6.7) |
| Missing | 3631 |
| Skin cancer at follow-up | |
| Any | 232 (3.7%) |
| Basal cell carcinoma | 88 (1.4%) |
| Melanoma | 44 (0.7% |
| ‘Skin’ | 100 (1.6%) |